西妥昔单抗（爱必妥）。
Cetuximab (erbitux).
机构信息
Department of Radiologyand, University of Michigan Health System, Ann Arbor, USA.
出版信息
AJNR Am J Neuroradiol. 2010 Apr;31(4):626-7. doi: 10.3174/ajnr.A2054. Epub 2010 Feb 18.
Abstract
Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.
摘要
西妥昔单抗是一种重组嵌合单克隆抗体，已成功用于头颈部和结直肠癌的治疗。我们对其作用机制、适应证、副作用和经济问题进行了综述，并结合我院的 1 例临床病例进行了介绍。
相似文献
1
Cetuximab (erbitux).西妥昔单抗（爱必妥）。
AJNR Am J Neuroradiol. 2010 Apr;31(4):626-7. doi: 10.3174/ajnr.A2054. Epub 2010 Feb 18.
2
Cetuximab: from bench to bedside.西妥昔单抗：从实验室到临床。
Curr Cancer Drug Targets. 2010 Feb;10(1):80-95. doi: 10.2174/156800910790980241.
3
IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.复发性头颈部癌的调强放疗再照射联合西妥昔单抗免疫治疗。
Strahlenther Onkol. 2011 Jan;187(1):32-8. doi: 10.1007/s00066-010-2149-7. Epub 2010 Dec 23.
4
The role of cetuximab in the treatment of squamous cell cancer of the head and neck.西妥昔单抗在头颈部鳞状细胞癌治疗中的作用。
Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. doi: 10.1517/14712598.5.8.1085.
5
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.嵌合型表皮生长因子受体（EGFR）抑制剂西妥昔单抗的输注反应——改用全人源抗EGFR单克隆抗体帕尼单抗是安全的。
Ann Oncol. 2011 Feb;22(2):486-7. doi: 10.1093/annonc/mdq744. Epub 2011 Jan 13.
6
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.英国国家卫生与临床优化研究所（NICE）关于西妥昔单抗、贝伐单抗和帕尼单抗用于一线化疗后转移性结直肠癌治疗的指南。
Lancet Oncol. 2012 Mar;13(3):233-4. doi: 10.1016/s1470-2045(12)70044-x.
7
Cetuximab: appraisal of a novel drug against colorectal cancer.西妥昔单抗：一种新型抗结直肠癌药物的评估
Recent Results Cancer Res. 2007;176:135-43. doi: 10.1007/978-3-540-46091-6_11.
8
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.单克隆抗体在结直肠癌中对表皮生长因子受体的临床应用。
Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7.
9
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.表皮生长因子受体作为癌症治疗靶点：IMC-C225在肺癌和头颈癌治疗中的新作用
Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36. doi: 10.1053/sonc.2002.31525.
10
The price tag on progress--chemotherapy for colorectal cancer.进步的代价——结直肠癌的化疗
N Engl J Med. 2004 Jul 22;351(4):317-9. doi: 10.1056/NEJMp048143.
引用本文的文献
1
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.治疗性结直肠癌疫苗：新兴模式与转化机遇
Vaccines (Basel). 2025 Jun 26;13(7):689. doi: 10.3390/vaccines13070689.
2
Fluorescence Imaging-Assessed Surgical Margin Detection in Head and Neck Oncology by Passive and Active Targeting.通过被动和主动靶向的荧光成像评估头颈部肿瘤手术切缘
Mol Diagn Ther. 2025 May 8. doi: 10.1007/s40291-025-00781-x.
3
Targeted cancer treatment using a novel EGFR-specific Fc-fusion peptide based on GE11 peptide.使用基于GE11肽的新型表皮生长因子受体（EGFR）特异性Fc融合肽进行靶向癌症治疗。
Sci Rep. 2025 Feb 11;15(1):5107. doi: 10.1038/s41598-025-89143-5.
4
Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.药物靶向、药物递送及纳米技术应用的进展：在癌症治疗中的治疗意义
Pharmaceutics. 2025 Jan 16;17(1):121. doi: 10.3390/pharmaceutics17010121.
5
A Case of Posterior Reversible Encephalopathy Syndrome Associated With Pembrolizumab and Cetuximab Combination Therapy.一例与帕博利珠单抗和西妥昔单抗联合治疗相关的后部可逆性脑病综合征病例。
Cureus. 2024 Oct 19;16(10):e71867. doi: 10.7759/cureus.71867. eCollection 2024 Oct.
6
Anti-anemic potential of L. in iron-deficient rat model; network pharmacology profiling.L. 在缺铁大鼠模型中的抗贫血潜力；网络药理学分析。
Food Sci Nutr. 2024 Jul 21;12(10):7331-7346. doi: 10.1002/fsn3.4314. eCollection 2024 Oct.
7
Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.西妥昔单抗通过抑制 Wnt/β-连环蛋白通路和调节 PLCB3 表达抑制结直肠癌的发展。
Sci Rep. 2024 May 9;14(1):10642. doi: 10.1038/s41598-024-59676-2.
8
A Multifunctionalized Potyvirus-Derived Nanoparticle That Targets and Internalizes into Cancer Cells.一种靶向并内化进入癌细胞的多功能马铃薯Y病毒衍生纳米颗粒。
Int J Mol Sci. 2024 Apr 13;25(8):4327. doi: 10.3390/ijms25084327.
9
Innovative Nanoparticulate Strategies in Colon Cancer Treatment: A Paradigm Shift.创新型纳米颗粒策略在结肠癌治疗中的应用：范式转变。
AAPS PharmSciTech. 2024 Mar 1;25(3):52. doi: 10.1208/s12249-024-02759-0.
10
Inhaled delivery of cetuximab-conjugated immunoliposomes loaded with afatinib: A promising strategy for enhanced non-small cell lung cancer treatment.吸入载有阿法替尼的西妥昔单抗免疫脂质体：增强非小细胞肺癌治疗的有前途策略。
Drug Deliv Transl Res. 2024 Nov;14(11):3147-3162. doi: 10.1007/s13346-024-01536-7. Epub 2024 Feb 21.
本文引用的文献
1
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.西妥昔单抗、紫杉醇、卡铂联合放疗治疗头颈部肿瘤：毒性分析。
Am J Clin Oncol. 2010 Apr;33(2):144-7. doi: 10.1097/COC.0b013e3181979093.
2
Emerging profile of cetuximab in non-small cell lung cancer.西妥昔单抗在非小细胞肺癌中的新作用。
Lung Cancer. 2010 Jun;68(3):332-7. doi: 10.1016/j.lungcan.2009.07.012. Epub 2009 Sep 26.
3
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.局部晚期头颈部癌症的西妥昔单抗、顺铂和氨磷汀放化疗：一项可行性研究。
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):9-15. doi: 10.1016/j.ijrobp.2009.04.060. Epub 2009 Sep 8.
4
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.癌症治疗中的抗表皮生长因子受体单克隆抗体
Clin Exp Immunol. 2009 Oct;158(1):1-9. doi: 10.1111/j.1365-2249.2009.03992.x.
5
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.西妥昔单抗用于转移性结直肠癌的前瞻性成本效益分析：加拿大国立癌症研究所临床试验组CO.17试验评估
J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.
6
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何：西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
7
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.西妥昔单抗联合放疗用于比利时、法国、意大利、瑞士及英国局部晚期头颈癌患者的经济学评估
Value Health. 2008 Sep-Oct;11(5):791-9. doi: 10.1111/j.1524-4733.2007.00302.x. Epub 2008 Jan 11.
8
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.西妥昔单抗：头颈部鳞状细胞癌及转移性结直肠癌应用综述
Drugs. 2007;67(17):2585-607. doi: 10.2165/00003495-200767170-00008.
9
Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.西妥昔单抗联合化疗对表达野生型和突变型表皮生长因子受体的非小细胞肺癌异种移植瘤的肿瘤生长抑制作用
Clin Cancer Res. 2007 Mar 1;13(5):1540-51. doi: 10.1158/1078-0432.CCR-06-1887.
10
Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.西妥昔单抗：一种用于治疗结直肠癌的表皮生长因子受体单克隆抗体。
Clin Ther. 2005 Jun;27(6):684-94. doi: 10.1016/j.clinthera.2005.06.003.
Zotero 插件